GlaxoSmithKline Pharmaceuticals (GSK Pharma) delivered December 2012 quarter results largely in line with expectations. The company grew its sales at a healthy 16% driven by new product launches across product categories.
GlaxoSmithKline Pharmaceuticals today reported a 1.29 per cent rise in its net profit at Rs 138.51 crore for the quarter ended December 31, 2012.The company had posted a net profit of Rs 136.74 crore for the corresponding period previous fiscal, the
India is not the only market where the London-headquartered GlaxoSmithKline (GSK) Plc has said that it would increase its stakeholding. The British major has also said that it would take up its ownership to 80 per cent in its Nigerian consumer business.
GlaxoSmithKline Plc plans to buy up to an additional 31.8% stake in its Indian consumer products arm for about 52.2 billion rupees ($940 million), as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health
GlaxoSmithKline is holding talks this weekend with Human Genome Sciences to agree a deal to acquire it for some $2.6 billion, after pursuing the US biotech firm for three months, sources familiar with the situation said on Sunday.
GlaxoSmithKline Pharmaceuticals today said its net profit rose by 18.18% to Rs 136.74 crore for the quarter ended December 31, 2011, over the same period last fiscal due to growth in its specialty products and vaccines.
Dragged down by lower growth of anti-infectives segment and rise in employee cost, GlaxoSmithKline (GSK) Pharmaceuticals today reported 7.57% decline in net profit for the third quarter ended September 30, 2011 to Rs 145.86 crore over the same period last
GlaxoSmithkline Pharmaceuticals today posted a massive decline in its net profit at Rs 46 lakh in the quarter ended March 31, from Rs 161 crore recorded in the corresponding period in the previous year.